Mirum Pharmaceuticals, Inc.
Moat Score — Mirum Pharmaceuticals, Inc.
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Mirum holds FDA/EMA approvals and regulatory exclusivity on Livmarli for rare cholestatic pruritus indications, but Ctexli and Cholbam already face generic/compounded competition with no remaining exclusivity, limiting the durability of this IP position. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a small commercial-stage rare-disease company, Mirum has no manufacturing or scale cost advantage versus larger pharmaceutical competitors like GSK, Ipsen, or Gilead in overlapping indications. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Orphan-drug pricing for rare, severe conditions like Alagille syndrome and CTX typically supports strong list pricing, but active generic/compounding competition on Ctexli and Cholbam, plus ongoing patent litigation over generic Livmarli, constrain how durable that pricing power is. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Rare-disease pharmaceutical sales carry no network effect between patients or prescribers. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Physicians and patients stabilized on a specific rare-disease therapy like Livmarli face real clinical caution about switching, but this is a modest, condition-specific form of stickiness rather than a strong structural lock-in, especially once generic alternatives exist for Ctexli and Cholbam. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The small patient populations for ALGS, PFIC, CTX, and bile acid synthesis disorders are generally too narrow to support more than one or two commercial competitors profitably, giving Mirum's first-mover approved products some natural protection against new entrants targeting the same indications. |